Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
CA 2519980 C · Owner: Salin-Drouin, Dominique · Inventors: Salin-Drouin, Dominique; Wepierre, Jacques; Rouanet, Philippe
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides methods for treating and preventing breast cancer by administering 4-hydroxy tamoxifen to a patient. It also provides pharmaceutical compositions of 4-hydroxy tamoxifen suitable for percutanous administration. When percutaneously administered to a patient's breasts 4-, hydroxy tamoxifen concentrates locally and exerts an anti-estrogenic effect. In patients with breast cancer, this effect reduces tumor tissue proliferation. In patients at risk for developing breast cancer the anti-, estrogenic effect prevents breast tumor formation.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 15, 2003 and granted April 10, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 15, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 15, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.